AG
VKTX icon

Algert Global’s Viking Therapeutics VKTX Stock Holding History

Algert Global’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,620
Closed -$215K – 1422
2026
Q1 		$215K Buy
+6,620
New +$213K ﹤0.01% 1069
2024
Q4 		– Sell
-31,264
Closed -$1.98M – 1350
2024
Q3 		$1.98M Sell
31,264
-2,280
-7% -$134K 0.05% 551
2024
Q2 		$1.78M Buy
33,544
+17,354
+107% +$1.14M 0.06% 505
2024
Q1 		$1.33M Buy
+16,190
New +$720K 0.05% 541

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Algert Global's VKTX Position: Q2 2026 in Review

Algert Global sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 6,620 shares — an estimated $215K sold.

Algert Global first reported a position in VKTX in Q1 2024 and held it in 4 quarters. The position peaked at $1.98M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Algert Global reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Algert Global sold 6,620 Viking Therapeutics shares in Q2 2026, an estimated $215K.
  • Algert Global first reported a position in Viking Therapeutics in Q1 2024 and held it in 4 quarters.
  • Algert Global's Viking Therapeutics position peaked at $1.98M in Q3 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.